DeCure for Familial atrial fibrillation

A 2020 report describes benign familial atrial fibrillation as rare, with a family of three members in excellent health apart from the arrhythmia. The authors stress that non-familial atrial fibrillation in otherwise healthy people is more common and is often wrongly labelled as serious disease, which can unjustly affect insurability. A 2017 study confirms that family history is an important risk factor, with several genetic regions implicated through genome-wide association studies. Familial atrial fibrillation is associated with earlier age of onset and fewer comorbid conditions than non-familial forms, and while symptoms are worse, all-cause mortality and thromboembolic risk are similar between familial and non-familial patients.

A 2003 review of pharmacologic management found strong evidence for acute conversion of atrial fibrillation using ibutilide, flecainide, dofetilide, propafenone, amiodarone, and quinidine compared with placebo. For maintaining sinus rhythm after conversion, strong evidence supported amiodarone, propafenone, disopyramide, and sotalol. For ventricular rate control, verapamil, diltiazem, atenolol, and metoprolol were qualitatively superior to digoxin and placebo, especially during exercise. For primary stroke prevention, evidence was strong for warfarin and suggestive for aspirin, with suggestive evidence of increased major bleeding risk for warfarin and inconclusive evidence for aspirin. The review noted that most patients have similar outcomes whether the strategy is rate control or rhythm control.

A 2008 review states that pharmacotherapy remains first-line therapy despite modern ablation, with the mainstay being prevention of thromboembolic events. New drug targets have been identified from growing knowledge of pathophysiology, promising individualised drug treatment. A 2020 review notes that despite advances, large differences in individual treatment responses remain and mechanisms of atrial fibrillation are not fully understood. International collaborations have revealed genetic contributions, and steps toward personalised management are being made. A 2023 review discusses genetic predictors of atrial fibrillation, pathogenetic mechanisms of atrial remodelling, assessment of genetic risk, prediction of outcomes and therapy effectiveness, and prospects for gene therapy.

What is still missing are large, prospective trials that stratify familial atrial fibrillation patients by specific genetic variants to test whether targeted therapies or gene therapy approaches improve outcomes beyond current rate and rhythm control. The cost of such trials and the difficulty of recruiting enough patients with defined familial genotypes remain barriers. No drug has been shown to modify the underlying genetic risk or to prevent the earlier onset seen in familial cases.